Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$722.5MBeat by $2.9M
EPS$0.27Beat by $0.10
Revenue estimate$719.7M
EPS estimate$0.17

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$768.2M
EPS estimate$0.24

Financials

Q1 2026

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$5.78B+126%
Enterprise value$8.15B+74.7%
P/E47.3×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Current ratio2.5×+1.1×

Segments

By product

See full
Subtotal dosage forms$417.9M+1.1%
Oral solid$171.1M-4.4%
Subtotal therapeutic classes$133.3M+23.1%
Distribution$89.1M-15.0%
Central nervous system$83.4M+23.3%

By segment

See full
AvKARE$166.0M-3.7%
Specialty$133.3M+23.1%

Versus estimates

Revenue

Q1 2026$722.5MBeat by $2.9M
Q4 2025$814.3MBeat by $7.0MQ3 2025$784.5MMiss by $21.6MQ2 2025$724.5MMiss by $44.1MQ1 2025$695.4MMiss by $48.8MQ4 2024$730.5MBeat by $7.4M

Diluted EPS

Q1 2026$0.27Beat by $0.10
Q4 2025$0.21Beat by $0.03Q3 2025$0.17Beat by $0.04Q2 2025$0.25Beat by $0.07Q1 2025$0.21Beat by $0.06Q4 2024$0.12Miss by $0.03

Ask the moment Amneal Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Amneal Pharmaceuticals, Inc. report Q1 2026 earnings?
Amneal Pharmaceuticals, Inc. (AMRX) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Amneal Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Amneal Pharmaceuticals, Inc. reported revenue of $722.5M and eps of $0.27 for Q1 2026.
Did Amneal Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $719.7M by $2.9M. EPS beat the consensus estimate of $0.17 by $0.10.
How did Amneal Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.9% from $695.4M a year earlier and eps grew 28.6% from $0.21.
Where can I find Amneal Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001723128-26-000019) and the 10-Q periodic report (0001723128-26-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.